TOKYO -- Japan's Takeda Pharmaceuticals has drawn closer to offering a first-of-its-kind treatment for narcolepsy, with the final phase of clinical studies set to launch this fall.
Takeda presented its findings from a Phase 2 trial of drug candidate TAK-861 during the joint annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society held early this month.
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
